SSG
KROS icon

Summit Securities Group’s Keros Therapeutics KROS Stock Holding History

Summit Securities Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69K Buy
+153
New +$2.36K ﹤0.01% 960

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Summit Securities Group's KROS Position: Q1 2026 in Review

Summit Securities Group opened a new position in Keros Therapeutics (KROS) in Q1 2026: 153 shares worth $1.69K. The stake represents ﹤0.01% of the portfolio and ranks #960 among its holdings.

151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Summit Securities Group held 153 shares of Keros Therapeutics worth $1.69K as of Q1 2026.
  • Keros Therapeutics was a new Summit Securities Group position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #960 holding.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.